The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: Its immunohistochemical evaluation using biopsy specimens

Lung Cancer

Volumn 26, Issue 3, 1999, Pages 187-194

  Ishihara, Shinichi ^a,b   Minato, Koichi ^b   Hoshino, Hideki ^b   Saito, Ryusei ^a   Hara, Futoshi ^b   Nakajima, Takashi ^b   Mori, Masatomo ^b  

^a Shibukawa Medical Center   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Advanced stage; Chemotherapy; Cyclin dependent kinase; Non small cell lung cancer; p27; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE; PROTEIN P27;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL;

AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0033490402     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00085-9     Document Type: Article

References (35)

1. Ministry of Health and Welfare, Statistics and Information Department. Vital Statistics, 1994 Japan. Vol. 3. Tokyo, 1996. p. 96-108.
2. Shottenfeld D. Epidemiology of lung cancer. Pass H., Mitchell J.B., Johnson D.H., Turrisi A.T. Lung Cancer: Principles and Practice. 1996;Lippincott-Raven Publishers, Philadelphia.
3. Catzavelos C., Tsao M.-S., DeBoer G., Bhattacharya N., Shepherd F.A., Slingerland J.M. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:1999;684-688.
4. Esposito V., Baldi A., Luca A.D., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
5. Giatromanolaki A., Koukourakis M.I., O'Byrne K., Kaklamanis L., Dicoglou C., Trichia E., Whitehouse R., Harris A.L., Gatter K.C. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res. 16:1996;3819-3825.
6. Kratzke R.A., Greatens T.M., Rubins J.B., Maddaus M.A., Niewoehner D.E., Niehans G.A., Geradts J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:1996;3415-3420.
7. Kwiatkowski D.J., Harpole Jr D.H., Godleski J., Herndon II J.E., Shieh D.-B., Richards W., Blanco R., Xu H.-J., Strauss G.M., Sugarbaker D.J. Molecular pathologic substaging in 244 stage I Non-small-cell lung cancer patients: clinical implications. J. Clin. Oncol. 16:1998;2468-2477.
8. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcimoma of the human lung without lymph node metastasis. Cancer Res. 52:1992;2903-2906.
9. Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T., Takahashi T. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinoma. Cancer Res. 58:1998;1042-1047.
10. Yu C.-J., Shun C.-T., Yang P.-C., Lee Y.-C., Shew J.-Y., Kuo S.-H., Luh K.-T. Sialomucin expression is associated with erbB-2 oncoprotein expression, early recurrence, and cancer death in non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 155:1997;1419-1427.
11. Kawasaki M., Nakanishi Y., Kuwano K., Yatsunami J., Takayama K., Hara N. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin. Cancer Res. 3:1997;1195-1200.
12. Takeuchi S., Mori N., Koike M., Slater J., Park S., Miller C.W., Miyoshi I., Koeffler H.P. Frequent loss of heterozygosity in region of the KIP 1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res. 56:1996;738-740.
13. Polyak K., Lee M.H., Erdjement-Bromage H., Koff A., Roberts J.M., Tempst P., Massague J. Cloning of p27/kip 1, a cyclin-dependent kinase inhibitor and a potentional mediator of extracellular antimitogenic signals. Cell. 79:1994;59-66.
14. Toyoshima T., Hunter T. p27, a novel inhibitor of G1-cyclin-cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
15. Ferro M.L., Rivkin M., Tasch M., Porter P., Carcow C.E., Firpo E., Polyak K., Tsai L.H., Broudy V., Perlmutter R.M., Kaushansky K., Roberts J. A syndrome of multiorgan hyperplasia with features of giantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 85:1996;733-744.
16. Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., Khanam D., Hayday A.C., Frohman L.A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 85:1996;721-732.
17. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido M., Horii I., Loh D.Y., Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720.
18. Hengst L., Dulic V., Slingerland J.M., Lees E., Reed S.I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA. 91:1994;5291-5295.
19. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
20. Slingerland J.M., Hengst L., Pan C.H., Alexander D., Stampfer M.R., Reed S.I. A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol. Cell Biol. 14:1994;3683-3694.
21. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K.I., Slingerland J.M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3:1997;227-230.
22. Fredersdorf S., Burns J., Milne A.M., Packham G., Fallis L., Gillett C.E., Royds J.A., Peston D., Hall P.A., Hanby A.M., Barnes D.M., Shousha S., O'Hare M.J., Lu X. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;6380-6385.
23. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:1997;231-234.
24. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:1997;222-225.
25. Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1997;1259-1263.
26. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 88:1997;625-629.
27. World Health Organization. Histological Typing of Lung Tumors. 2nd ed. Geneva: WHO, 1981. p. 25-6.
28. Mountain C.F. A new international classification system for lung cancer. Chest. 89(Suppl.):1986;225-233.
29. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer. 35:1977;1-39.
30. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
31. Espinosa E., Feliu J., Zamora P., Baron M.G., Sanchez J.J., Ordonez A., Espinosa J. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 12:1995;67-76.
32. Takigawa N., Segawa Y., Okahara M., Maeda Y., Takata I., Kataoka M., Fujii M. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer. 15:1996;67-77.
33. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat. Rep. 62:1978;1117-1133.
34. Croix B.S., Florenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., Kerbel R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2:1996;1204-1210.
35. De Vita V.T.J. The cell cycle, drug resistance, and the p53 tumor suppressor gene pathway. De Vita V.T.J., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 5th edn:1997;338-342 J.B. Lippincott Co, Philadelphia.